(NASDAQ: TRDA) Entrada Therapeutics's forecast annual revenue growth rate of 146.74% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.61%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.99%.
Entrada Therapeutics's revenue in 2026 is $3,977,000.On average, 9 Wall Street analysts forecast TRDA's revenue for 2026 to be $571,751,478, with the lowest TRDA revenue forecast at $69,061,189, and the highest TRDA revenue forecast at $2,055,392,535. On average, 9 Wall Street analysts forecast TRDA's revenue for 2027 to be $1,522,752,241, with the lowest TRDA revenue forecast at $137,339,372, and the highest TRDA revenue forecast at $3,083,088,803.
In 2028, TRDA is forecast to generate $2,304,036,306 in revenue, with the lowest revenue forecast at $137,339,372 and the highest revenue forecast at $7,193,873,873.